Abnormal functions of this MVE lead to abnormal haemostasis that may be involved in both encephalopathy and acute respiratory distress, a novel therapy to alleviate this failure from its molecular origins consists in the use of tissue factor pathway inhibitor (TFPI). This evidence concerns the gene TFPI and Encephalopathy.